OmniPathology Celebrates
Grand Opening of New Laboratory
in Pasadena

OmniPathology, a leader in advanced pathology and molecular diagnostics testing, proudly celebrated the Grand Opening of its new world-class laboratory in Pasadena, CA, on January 28, 2025. Over 100 guests—including executive members of the healthcare community, media, press, family, and friends—were in attendance to mark the major milestone of the company’s innovations in molecular diagnostics, pathology, and women’s health.

 “A heartfelt thank you to all the brilliant doctors, esteemed colleagues, and supportive friends and family who joined us for this milestone event,” said Dr. Mohammad Kamal, OmniPathology’s Medical Director and CEO. “Your presence made our Grand Opening truly special!”

Highlights of the Grand Opening

  • During the ceremony, leadership and esteemed guests recognized the hard work and commitment of the doctors, laboratory professionals, administrative staff, and support teams who have made OmniPathology what it is today. “This momentous event would not have been possible without the dedication, expertise, and passion of the incredible team behind it,” said Dr. Kamal.

  • Dr. Ibrahim Ramzy, Professor Emeritus of Pathology, University of California, Irvine School of Medicine, presented Dr. Kamal with an antique microscope from 1915. “I want to express my deep appreciation for this profound symbol of the rich history of pathology,” said Dr. Kamal. “We honor the legacy of the pioneering pathologists who paved the way for our current understanding of disease, while continuing to push the frontiers of knowledge and innovation in our field.”

  • Vice President of Operations Michelle Herrera spoke about the numerous challenges the team faced during the COVID pandemic. OmniPathology was among the first labs in the country to develop, validate, and receive Emergency Use Authorization (EUA) to perform real-time molecular COVID testing on patients. Herrera successfully spearheaded the Omni Classroom community program across Greater Los Angeles to test children, their families, and school staff for COVID and other respiratory infections.

  • Dr. Ronald A. Blum, Vice President of Science & Technology, spoke about the future growth of the company, including expanding its clinical trials capabilities, the introduction of digital pathology and artificial intelligence (AI), and the excitement around its new patent-pending oropharyngeal HPV assay to screen patients at increased risk of throat cancer.

  • Guests had the opportunity to tour the world-class facility, guided by Dr. Kamal himself. Capabilities of the new lab include anatomic pathology, histopathology, cytology, fluorescent in situ hybridization (FISH), immunohistochemistry/in situ hybridization (IHC/ISH), real-time PCR, and next generation sequencing (NGS).